ArticleCancer cell international2024

NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route.

Obed Boadi Amissah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.